Validation of PhageDx™ Salmonella Assay in Raw Ground Turkey and Powdered Infant Formula: AOAC Performance Tested MethodSM 121904

Steve Erickson¹, Jose Gil², Jessica Stach¹, and Minh M. Nguyen¹

¹Laboratory Corporation of America®/MedTox, 402 County Road D West, St. Paul, MN 55112
²Laboratory of America Corporation®/National Genetics Institute, 2440 Sepulveda Blvd., Suite 235, Los Angeles, CA 90064

Corresponding author's e-mail: Nguyem5@LabCorp.com

Abstract

Background: The PhageDx™ Salmonella Assay is based on the infection of Salmonella spp. by specific bacteriophages and expression of a luciferase reporter gene. Results are generated in as little as 9.5 h for raw ground turkey and 18.5 h for milk-based powdered infant formula (PIF).

Objective: An AOAC Performance Tested MethodsSM (PTM) study was conducted to validate the PhageDx™ Salmonella Assay for the detection of Salmonella in 25 g raw ground turkey and 100 g Powdered Infant Formula (PIF) test portions.

Methods: The performance of the PhageDx™ Salmonella Assay was compared to that of the USDA/FSIS MLG 4.10 for raw ground turkey and FDA/BAM Chapter 5 for PIF. Inclusivity/exclusivity, product consistency and stability, and robustness testing were conducted.

Results: There was no significant difference between the 25 g raw ground turkey and 100 g PIF PhageDx™ Salmonella Assay and the USDA/FSIS MLG 4.10 and FDA/BAM Chapter 5, respectively. The reporter bacteriophages were specific for Salmonella and infected 108 strains in inclusivity testing. They did not infect 30 non-Salmonella bacteria in exclusivity testing. Robustness testing showed that the method performed well with specific deviations from the standard protocol.
Consistency and stability testing demonstrated that the recombinant phage gave consistent results across three production lots and was stable when stored under appropriate conditions for at least six months.

Conclusions and Highlights: The data collected in the validation study demonstrate that the PhageDx™ Salmonella Assay meets the qualifications for PTM status.

General Information

Salmonella is a genus of rod-shaped Gram-negative bacteria of the family Enterobacteriaceae. There are two species of Salmonella, Salmonella bongori and Salmonella enterica. S. enterica is further divided into six subspecies that include over 2600 serotypes and is responsible for a majority of reported Salmonella related illnesses (1).

The USDA has ranked Salmonella as one of the costliest foodborne illness, resulting in an estimated $3.7 billion in medical costs each year (2). The most common symptoms of a Salmonella infection include diarrhea, fever and abdominal cramps and many recover without treatment. However, some cases can be so severe that they can result in hospitalization or death. The CDC estimates that Salmonella causes about 1.2 million illnesses, 23,000 hospitalizations, and 450 deaths in the United States every year. Contaminated food accounts for about 1 million of these illnesses. In 2019, there were several outbreaks linked to papayas, tahini, raw tuna, melon, and ground turkey (3). In addition, Salmonella contamination in powdered infant formula remains a problem in many parts of the world (4).

Principle of the Method

The PhageDx™ Salmonella Assay is based on the infection of Salmonella spp. by bacteriophages and replication of the infecting bacteriophages within their specific hosts. Bacteriophages demonstrate a high specificity for their bacterial host and are capable of replicating within their host quickly to high numbers. The recombinant phages used in the PhageDx™ Salmonella Assay also express a luciferase reporter during replication. The presence of Salmonella spp. is
determined by incubating the lysate with the appropriate luciferase substrate and detecting emitted light in a luminometer. An absence of detected light indicates that no *Salmonella* are present in that sample. An additional advantage of this system is that only viable bacteria cells are detected as bacteriophage only replicate in living cells.

**Scope of method**

(a) **Target organism.**—*Salmonella* spp.

(b) **Matrix.**—Raw ground turkey and powdered infant formula (milk-based)

(c) **Summary of Validated Performance Claims.**—Performance equivalent to that of the United States Department of Agriculture Food Safety and Inspection Service *Microbiology Laboratory Guidebook* 4.10, *Isolation and Identification of Salmonella from Meat, Poultry, Pasteurized Egg, and Siluriformes (Fish) Products and Carcass and Environmental Sponges* (USDA/FSIS MLG 4.10) for raw ground turkey, and the U.S. Food and Drug Administration *Bacteriological Analytical Manual* Chapter 5 *Salmonella* (FDA/BAM Chapter 5) for milk-based powdered infant formula (5,6).

**Definitions**

(a) **Probability of Detection (POD).**—The proportion of positive analytical outcomes for a qualitative method for a given matrix at a given analyte level or concentration. POD is concentration dependent. Several POD measures can be calculated: POD_{R} (reference method POD), POD_{C} (confirmed candidate method POD), POD_{CP} (candidate method presumptive result POD) and POD_{CC} (candidate method confirmation result POD).

(b) **Difference of Probabilities of Detection (dPOD).**—Difference of probabilities of detection is the difference between any two POD values. If the confidence interval of a dPOD does not contain zero, then the difference is statistically significant at the 5% level.
Materials and Methods

Test Kit Information

For raw ground turkey

(a) Kit Name. — PhageDx™ Salmonella Assay.

(b) Catalog Number. — 5009.

(c) Ordering Information. — Not applicable. For internal use at Laboratory Corporation of America only.

Test Kit Components

(a) PhageDx™ Salmonella recombinant phage. — Part. No. 3201, 12 tubes containing 100 µL Phage solution.

(b) Lysis buffer. — Part. No. 3010, 12 tubes containing 150 µL Lysis buffer.

(c) Assay buffer. — Part. No. 3003, 12 tubes containing 500 µL Assay buffer.

(d) Luciferase substrate. — Part. No. 3004, 12 tubes containing 10 µl Luciferase substrate.

(e) 96-well break-apart plate. — Part. No. 3005, one pouch containing white break-apart plate (8 wells × 12 strips).

(f) One package insert. — Part. No. 3202.

Additional supplies and reagents

(a) Sample bags. — WhirlPak® Sterile Filter Bags for Lab Blenders, 24oz, Cat#. Nasco B01348WA or similar.

(b) Microfuge tubes (1.5 mL).
(c) Racks for sample bag and tubes.

(d) Buffered Peptone Water (BPW).—Thermo Scientific™ Oxoid™ Cat. No.OXCM0509R.

(e) Adjustable single channel pipettors (10 µL–1 mL) and appropriate sterile filtered tips.

(f) Appropriate personal protective equipment.—See

https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF.

For confirmation (optional)

(g) Dynabeads™ anti-Salmonella. —ThermoFisher™ Cat. No. 71002.

(h) DynaMag™-2.—or similar, ThermoFisher™ Cat. No. 12321D.

(i) DRG International CHROMagar™ Salmonella.—Cat. No. SA132.

For powdered infant formula

Test Kit Information

(a) Kit Name.—PhageDx™ Salmonella Assay.

(b) Catalog Number.—5011.

(c) Ordering Information.—Not applicable. For internal use at Laboratory Corporation of America only.

Test Kit Components

(a) PhageDx™ Salmonella recombinant phage.—Part. No. 3201, 12 tubes containing 100 µL phage solution.

(b) Lysis buffer.—Part. No. 3010, 12 tubes containing 150 µL Lysis buffer.

(c) Assay buffer.—Part. No. 3003, 12 tubes containing 500 µL Assay buffer.

(d) Luciferase substrate.—Part. No. 3004, 12 tubes containing 10 µl Luciferase substrate.

(e) 96-well break-apart plate.—Part. No. 3103, one pouch containing black break-apart plate (8 wells × 12 strips).
(f) One package insert.—Part. No. 3203.

Additional supplies and reagents

(a) Sample bags.—Fisher Scientific Cat. No. 14955196 or similar.

(b) Microfuge tubes (1.5 mL).

(c) Racks for Sample bag and tubes.

(d) Buffered Peptone Water (BPW), Thermo Scientific™ Oxoid™ Cat. No. OXCM0509R.

(g) Adjustable single channel pipettors (10 µL–1 mL) and appropriate sterile filtered tips.

(h) Appropriate personal protective equipment. —See https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF.

For confirmation (optional)

(a) DRG International CHROMagar™ Salmonella, Cat. No. SA132.

Apparatus

(a) Homogenizer.— Stomacher® 400/Stomacher® 3500 or similar.

(b) Air incubators capable of 37 ± 1°C, 41± 1°C.

(c) Promega GloMax® 96 or Navigator luminometer.

(e) Personal computer for luminometer control and data analysis.

Safety Precautions
(a) The PhageDx™ Salmonella Assay involves the enrichment of samples which may contain human pathogenic Salmonella and have the potential for contamination with subsequent handling of those samples. This method should be conducted by properly trained laboratory personnel in a suitable microbiology laboratory in accordance with “Biosafety in Microbiological and Biomedical Laboratories”, U.S. Department of Health and Human Services, https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF. Care should be taken when handling the sample and reagents while performing the method.

(b) Materials and reagents provided in the PhageDx™ Salmonella Assay are not considered hazardous if used according to the assay method. Please review the Material Safety Data Sheet prior to performing the assay.

(c) Follow all relevant guidelines and laboratory protocols while performing the assay and manufacturer’s equipment instructions.

General Preparation

(a) Prepare BPW media according to manufacturer’s instructions.

(b) Before using the reagents, flick or spin the tube to collect all of the solution at the bottom of the tube.

(c) Due to the short enrichment times, it is vital to maintain the temperature of the sample and BPW media used in the enrichment incubation.

(d) Before adding the pre-warmed BPW to the sample, confirm that the media and incubator are warmed to 37 ± 1°C (PIF) or 41 ± 1°C (raw ground turkey).

(e) Do not allow the pre-warmed media to cool before adding to the sample.

(f) Maintain the media at 37 ± 1°C or 41 ± 1°C in an incubator or water bath if preparing multiple samples.

(g) Prepare the Promega luminometer by following the manufacturer’s cleaning procedure and make sure there are no signal “hot spots” that will affect the sample results by reading an empty plate. All signals should be less than 20
RLU. Set up the luminometer to read the appropriate wells on the plate and set the signal integration to 1 second with a 180 second delay between starting the program and the signal read.

*Sample Preparation*

**Raw Ground Turkey (25 g test portion)**

(a) Weigh 25 g of raw ground turkey and place into a filter sample bag.

(b) Add 75 ± 5 mL pre-warmed (41 ± 1°C) BPW to the sample.

(c) Homogenize sample in a Stomacher® 400 or equivalent. Alternatively, mix by hand.

(d) Loosely close the sample bag and place in a static air incubator at 41 ± 1°C for 7–18 h using a sample rack to keep the bags separate and allow heat transfer.

(e) Remove the enriched samples from the incubator and mix thoroughly by hand for 15–30 s. and immediately proceed to the next step after mixing is completed. If sample sits for 15 minutes or longer, mix sample again before proceeding to the next step. *NOTE: It is critical that the enrichment is mixed well to ensure even distribution of target analyte before taking a sample aliquot.*

(h) Using PhageDx™ *Salmonella* Kit Cat. No. 5009 - Using a single channel pipettor and fresh sterile tip for each sample, transfer 150 µL of enriched sample to white 96-well break-apart plate taking care to avoid transferring fat and meat particles as much as possible.

**For PIF (100 g test portion)**

(a) Weigh 100 g of powdered infant formula and place into a sample bag.

(b) Add 300 ± 5 mL pre-warmed (37 ± 1°C) BPW to the sample.

(c) Homogenize sample in a Stomacher® 3500 at the highest setting for 120 s (or equivalent homogenizer and setting).
(d) Loosely close the sample bag and place in a static air incubator at 37 ± 1°C for 16–24 h using a sample rack to keep the bags separate and allow heat transfer.

(e) Remove the enriched samples from the incubator and mix thoroughly by hand for at least 30 s to ensure complete mixing. **NOTE: Sample must be thoroughly mixed so that analyte is distributed evenly throughout the entire sample. We recommend vigorous shaking and massaging for at least 30 s and proceeding immediately to the next step after mixing is complete. If sample sits for 15 min or longer, mix sample again before proceeding to the next step.**

(f) Using a sterile tip/pipet, transfer 1 mL of the sample to a sterile 1.5 mL microfuge tube.

(g) Mix contents in microfuge tube and dilute sample 1:10 in BPW (100 µL sample in 900 µL BPW) into a fresh sterile 1.5 mL tube.

(h) Using a single channel pipettor and clean tip for each sample, transfer 150 µl of diluted sample to black 96-well break-apart plate.

For both matrixes

(i) After transferring samples to 96-well plates, using a single channel pipettor and clean tip for each sample, add 10 µL of the phage solution to the sample and gently mix by pipetting up and down.

(j) Cover plate with sealing tape to prevent cross contamination and evaporation. Place the sample in the 37 ± 1°C incubator for 2 h.

(k) Remove one tube containing the lysis buffer, assay buffer, and substrate for each 8 well strip used and thaw to room temperature. Flick or spin the tubes to collect all of the solution at the bottom of the tubes.

(l) Prepare the lysis/luciferase master mix by transferring the entire contents of assay buffer (0.5 ml) and lysis buffer (150 µL) tubes to the substrate tube (10 µL) and mix well. **NOTE: Use within 1 h of preparation**

(m) Add 65 µL of the lysis/luciferase master mix to each well using a single channel pipettor. Mix thoroughly by pipetting up and down. To avoid cross-contamination, use a clean tip for each sample.
Once all of the samples have received the lysis/luciferase master mix, place the sample plate in the luminometer, close the lid and initiate the read program.

*Interpretation and Test Result Report*

(a) The luminometer program will display the results on the screen as relative light unit (RLU) values corresponding to the well positions of the break-apart plate.

(b) For raw ground turkey, samples positive for *Salmonella* will have a reading value of 750 RLU or greater for a 7–13 h enrichment or 50,000 RLU or greater for >13–18 h enrichment. Negative samples will be less than 750 RLU for a 7–13 h enrichment and less than 50,000 RLU for >13–18 h enrichment.

(c) For powdered infant formula, samples positive for *Salmonella* will have a reading value of 500 RLU or greater. Negative samples will be less than 500 RLU.

*Note:* In some cases, the PhageDx™ *Salmonella* Assay will generate a very high signal and result in adjacent wells to read as a false positive due to the bleed over from the well with high signal. If a sample well is positive and has a 1000X lower signal than the adjacent sample well with a higher signal, this could be a result of bleed over. In these cases, we recommend that the contents of the potential false positive well (lower RLU sample) be transferred to a new well at least 2-3 well distance from the high signal well or to a new strip and re-read to confirm that the signal is from the sample and not a result of bleed over signal.

Once all of the samples have been run and analyzed, remove the plate from the luminometer and follow the manufacturer’s instructions for cleaning the instrument and shut down.
Confirmation

We recommend that presumptive positives from the phage assay be confirmed.

(a) For raw ground turkey, confirmation for Salmonella can be performed on overnight enriched samples using immuno-magnetic separation (IMS) particles coated with Salmonella antibodies (Dynabeads™ anti-Salmonella, ThermoFisher Cat. No. 71002) to capture Salmonella (use according to manufacturer’s instructions), and plating onto chromogenic Salmonella selective plates (DRG International CHROMagar™ Salmonella, Cat. No. SA132), and allowed to incubate for an additional 24 ± 2 h at 37 ± 1°C.

(b) For powdered infant formula, confirmation of Salmonella spp. can be performed by streaking samples enriched for a total of 24 ± 2 h directly onto Salmonella chromogenic selective plates (DRG International CHROMagar™ Salmonella, Cat. No. SA132). To prepare for the confirmation, allow the samples to continue enriching for a total of 24 ± 2 h at 37 ± 1°C. Remove 50–100 µL of the overnight culture and streak onto selective agar plates and incubate plates for 24 ± 2 h at 37 ± 1°C.

(c) Plates with colonies that appear mauve and are 1–3 mm in diameter indicate a positive result for Salmonella (Refer to manufacturer’s product insert for detailed description).

(d) Alternatively, the user may use an approved reference method confirmation protocol.

Validation Study

This validation study was conducted under the AOAC Research Institute Performance Tested Method℠ program and the AOAC INTERNATIONAL Methods Committee Guidelines for Validation of Microbiological Methods for Food and Environmental Surfaces, Appendix J (7). Method developer studies were conducted in the laboratories of Laboratory Corporation of America Holdings, and included the inclusivity/exclusivity study, product consistency and stability studies, and robustness testing. The Independent Laboratory Study was conducted by Q Laboratories, Inc., and included...
inclusivity study for selected strains and matrix studies for all claim matrixes.

*Method Developer Studies*

*Inclusivity and Exclusivity Studies*

Inclusivity strains (*Salmonella*) were obtained from academic, governmental, and commercially available sources. Each strain was grown overnight to stationary phase in BPW media at 37 ± 1°C. The overnight cultures were then diluted to 1000 CFU/mL in BPW. One-hundred microliters of diluted cells were used to inoculate 2 X 9.9 mL of BPW to a concentration of 10 CFU/mL. Samples were then allowed to incubate at 41 ± 1°C for 7 or 18 h. At each time point, a 150 µL sample was taken for evaluation. To evaluate each strain, cells were infected with phage solution at 37 ± 1°C for 2 h. Lysis/luciferase master mix was added, and the sample was read on the luminometer. Samples enriched for 7 h with signals >750 RLU were considered positive. Strains with <750 RLU were tested again using 18 h enriched samples. Samples enriched for 18 h with >50,000 RLU were considered positive (Table 1). Exclusivity strains were also obtained from commercially available sources and were grown to stationary phase overnight. Assays with exclusivity strains were done as with inclusivity strains except overnight cultures were assayed without dilution (Table 2).

*Results.*—The PhageDx™ *Salmonella* Assay demonstrates inclusivity for the 108/110 *Salmonella* strains tested (Table 1). The PhageDx™ Assay also demonstrates exclusivity for 30/30 non-*Salmonella* strains tested (Table 2).

*Product Consistency (lot-to-lot) and Stability Studies*

Three separate production lots of PhageDx™ *Salmonella* recombinant phage were prepared according to written manufacturing documents and tested according to quality control procedures. Quality control procedures verified that each lot when diluted to working concentration had the same titer, background and level of detection. Recombinant
Phage reagents were aged between 1 and 6 months when assayed for stability.

Consistency and stability were done according to AOAC guidance, where a sample was inoculated with *S. typhimurium* (ATCC 19585) to give fractional positives. Ten replicates were run in the PhageDx™ Assay, and the RLU values analyzed. A set of stability studies was also conducted using the non-target bacterium *Citrobacter freundii* (ATCC 8090). Overnight cultures of *C. freundii* were used directly in the assay. Results are shown in Table 3.

**Results.**—The PhageDx™ *Salmonella* recombinant phages can be manufactured consistently and are stable for at least 6 months when stored at 4°C. Manufactured lots were made on 12/18, 3/19, and 8/19 according to written manufacturing documents. Working solutions of each lot produced similar results when tested according to QC control tests for bacteriophage concentration, background signal and limit of detection. Stability tests of each lot were performed to determine the shelf life of the recombinant phage. These tests demonstrated that lots produced 1 month prior to testing showed no significant difference from lots produced at least 6 months prior to testing. Additionally, no variation in exclusivity was observed with these three recombinant phage lots in tests with *C. freundii*.

**Robustness Study**

Three parameters were varied to demonstrate assay robustness: enrichment time (6.5 and 24 h), recombinant phage concentration (± 20%) and lysis/luciferase master mix amount (±5 µL). Briefly, 25 g raw ground turkey samples were left unspiked or spiked with 0.2–2 CFU/25 g with *S. Heidelberg* SL476 and stored at 2–8°C for 48–72 h. The PhageDx™ *Salmonella* Assay protocol was followed with the variations in enrichment time, recombinant phage concentration and lysis/substrate master mix amounts as indicated in Table 4. Samples with RLU values greater than 750 were considered positive for 6.5 and 7 h enriched samples and RLU values greater than 50,000 were considered positive for the 24 h enriched samples. Samples were confirmed by allowing samples to enrich overnight and performing IMS with anti-*Salmonella* coated particles and plating on chromogenic *Salmonella* selective plates. The presence of mauve colonies that are 1–3 mm in diameter on selective plates indicate a positive result for *Salmonella*. A summary of the
testing is presented in Table 4.

Results. —Robustness testing of the PhageDx™ Salmonella Assay demonstrated that variations in enrichment time, recombinant phage concentration and lysis/luciferase master mix amounts do not alter the results compared to the standard protocol. Enrichment times of 6.5 and 24 h, recombinant phage volumes of 8 and 12 µL and lysis/luciferase master mix volumes of 60 and 70 µL produced identical results to the standard protocol of 7 h enrichment, 10 µL of recombinant phage and 65 µL of lysis/luciferase master mix in both uninoculated and low inoculum test samples (Table 4). These results indicate that these deviations from the PhageDx™ Salmonella Assay protocol did not alter the final results.

Independent Laboratory Validation Study

Inclusivity

For the inclusivity study six strains of Salmonella were evaluated. Each Salmonella strain evaluated was cultured by transferring a single colony from trypticase soy agar with 5% sheep blood (SBA) to a 9 mL aliquot of BPW for 7 h at 41 ± 1°C, and to a second 9 mL aliquot of BPW for 16 h at 37 ± 1°C. After incubation each Salmonella strain at each culture condition was then diluted to 100x the Limit of Detection (LOD) of the PhageDx™ Salmonella Assay and analyzed. Tests results were reported as either positive or negative (Table 1).

Matrix Study
The independent laboratory evaluation included matrix studies for raw ground turkey and milk based PIF comparing the PhageDx™ *Salmonella* Assay to USDA/FSIS MLG 4.10 and FDA/BAM Chapter 5, respectively. Within each sample set, there were 5 uninoculated samples (0 CFU/ test portion), 20 low-level inoculated samples (0.2–2 CFU/ test portion), and 5 high-level inoculated samples (2–10 CFU/ test portion). The low inoculation level was designed to produce fractional positive results in which the candidate or reference method produced 5–15 positive results (25–75%).

The raw ground turkey and milk-based powdered infant formula were purchased from a local supplier and prescreened for natural contamination of the analyte following USDA/FSIS MLG 4.10 and the FDA/BAM Chapter 5 reference methods, respectively. Total aerobic count was determined following FDA BAM Chapter 3 Aerobic Plate Count reference method (8). Following the screening, the matrixes were inoculated with the indicated strains of *Salmonella* species. For raw ground turkey matrix, a liquid inoculum culture was used. The inoculum was prepared by transferring a single *Salmonella* colony from a stock culture stored at -70°C on SBA into brain heart infusion (BHI) broth and incubating the culture at 35 ± 1°C for 24 ± 2 h. Following incubation, the culture was diluted to a target level using BHI as the diluent to a low level expected to yield fractional positive results (5–15 positive results), and a high level expected to yield all positive results. Samples were spiked and held for 48–72 h post-inoculation at 2-8°C to allow for equilibration of the organism as per AOAC guidelines.

For the milk-based powdered infant formula matrix a lyophilized culture was used. *Salmonella* were cultured from stock stored at -70°C on SBA for 18 hr at 37°C. The lyophilized culture was prepared by inoculating BHI broth with a single colony from SBA and incubating for 18-24 h at 35 ± 2°C, diluting the culture into a sterile cryoprotectant, adding non-fat dried milk (NFDM), and freeze-dried for 48-72 h. The culture was then diluted in a sterile cryoprotectant, reconstituted non-fat dry milk (NFDM), and freeze dried for 48–72 h. A bulk lot of the matrix was inoculated with a lyophilized culture that was diluted in powdered NFDM to a low level expected to yield fractional positive results (5–15 positive results), and a high level expected to yield all positive results. After inoculation, samples were held for 2 weeks at room temperature (24 ± 2°C) to allow for equilibration of the organism as per AOAC guidelines. For all 100 g test
portions analyzed, 25 g of inoculated matrix at each level of contamination was transferred to sterile filter laboratory
blender bags on the day of analysis, and then 75 g of uninoculated matrix added to create 100 g test portions.

The level of *Salmonella* in the low-level inoculum and high-level inoculum was determined by Most Probably
Number (MPN) on the day of analysis. For the 25 g test portion samples, low-level inoculum MPN was determined by
evaluating 5 x 50 g, 20 x 25 g reference method test portions from the study, and 5 x 10 g inoculated test portions. The
level of *Salmonella* in the high-level inoculum in 25 g test portions was determined by evaluating the 5 x 25 g reference
method test portions from the study, 5 x 10 g and 5 x 5 g inoculated test portions. To the 50 g portions 450 mL of the
reference method enrichment broth was added, to the 10 g portions 90 mL of the reference method enrichment broth
was added, and to the 5 g portions 45 mL enrichment broth was added. All 25 g portions were utilized from reference
method test portions and analyzed following the FDA/BAM Chapter 5 reference method. The number of positives from
the 3 test levels was used to calculate the MPN using the LCF MPN calculator (version 1.6)(9).

**PhageDx™ Salmonella Assay**

All samples were analyzed by the PhageDx™ *Salmonella* Assay following enrichment with pre-warmed (41 ± 1°C)
BPW and incubated for 7 and 18 h at 41 ± 1°C for raw ground turkey, and enrichment with pre-warmed (37 ± 1°C) BPW
and incubated for 16 and 24 h at 37 ± 1°C for milk-based powdered infant formula. After enrichment, a 150 µL direct
sample for raw ground turkey, or a 150 µL 1:10 diluted sample for PIF, was transferred to a 96-well plate. Ten microliters
of the phage reagent were added and samples were incubated at 37 ± 1°C for 2 h. Then, 65 µL of lysis/luciferase master
mix was added and the samples read on a luminometer. Regardless of presumptive results, all samples were culturally
confirmed by the USDA/FSIS MLG 4.10 or FDA/BAM Chapter 5 reference method. In addition, all samples were
confirmed following the alternative confirmation described previously in “Sample Preparation”, subsection “Confirmation”. Final confirmation for all samples was obtained by Bruker MALDI Biotyper following AOAC OMA 2017.09 (10).

USDA/FSIS MLG 4.10

For the USDA/FSIS MLG 4.10, 25 ± 2.5 g of raw ground turkey portions were combined with 225 ± 4.5 mL of Buffered Peptone Water (BPW), homogenized by stomaching for 2 min and incubated 18–24 h at 35 ± 2°C. After incubation of all test portions, 0.5 ± 0.05 mL of the sample enrichment was transferred into 10 ± 0.5 mL of Tetrathionate Broth Hajna (TT Hajna), and 0.1 ± 0.02 mL of the sample enrichment was transferred into 10 mL ± 0.5 mL of Modified Rappaport Vassiliadis Medium (mRV). The secondary enrichments were incubated in a circulating, thermostatic water bath at 42 ± 0.5°C for 18–24 h.

After 18–24 h, the contents in the TT and mRV enrichments were mixed by vortex and a loopful of each streaked to XLT4 and BGSA. All plates were incubated at 35 ± 2°C for 18–24 h. After incubation, plates were observed for typical and well-isolated colonies. One typical colony for each positive sample was picked to Triple Sugar Iron agar (TSI) and Lysine Iron Agar (LIA) slants, along with Tryptic Soy Agar (TSA) plates, and incubated for 24 ± 2 h at 35 ± 2°C. Following incubation, the slants were examined as a set and the biochemical reactions of the slants noted. Final confirmation was obtained from purified TSA isolates using the Bruker MALDI Biotyper following AOAC OMA 2017.09.

FDA/BAM Chapter 5 Salmonella

For the FDA/BAM reference method, 25 g milk-based powdered infant formula portions were combined with 225 ± 5 mL of Lactose Broth and homogenized by stomaching for 2 min. Following homogenization, test portions were
allowed to stand at room temperature (24 ± 2°C) for 60 ± 5 min. If necessary, the pH of the enrichments for all matrices was adjusted to 6.8 ± 0.2. Subsequently, all matrix enrichments were incubated at 35 ± 2°C for 24 ± 2 h.

Following incubation, 0.1 mL of primary enrichment was transferred into 10 mL of RV and 1.0 mL into 10 mL of TT medium. RV tubes were incubated at 42 ± 0.2°C for 24 ± 2 h. The milk-based powdered infant formula tested had a low microbial background (<10⁴ CFU/g); therefore, the TT tubes were incubated at 35 ± 2°C for 24 ± 2 h. Following incubation, a loopful of the secondary enrichments were streaked to BS, HE and XLD and incubated at 35 ± 2°C for 24 ± 2 h. If no visible colonies were present after 24 h of incubation on the BS plates, they were re-incubated for an additional 24 ± 2 h at 35 ± 2°C. A minimum of two suspect colonies from each selective agar were transferred to TSI and LIA slants and incubated at 35 ± 2°C for 24 ± 2 h. Following incubation, TSI and LIA slants were examined for typical reactions. Slants producing typical reactions were streaked to TSA and incubated for 35 ± 2°C for 18–24 h.

Following incubation, isolates were serologically tested for both somatic O and flagellar H agglutination. Additionally, final confirmation was obtained from purified TSA isolates using the Bruker MALDI Biotyper following AOAC OMA 2017.09.

Results. — In an unpaired study, the presumptive results from the PhageDx™ Salmonella Assay for raw ground turkey (7 and 18 h enrichments) and PIF (16 and 24 h enrichments) were not significantly different from those of the USDA/FSIS MLG 4.10 and FDA/BAM chapter 5, respectively. In a paired study, the results from the PhageDx™ Salmonella Assay presumptive, PhageDx™ confirmation method, and the respective reference methods were identical (Table 6). In addition, no false positive or false negatives were detected in the matrix study. In summary, independent laboratory matrix tests demonstrated that the results from PhageDx™ Salmonella Assay and the USDA/FSIS MLG 4.10 and FDA/BAM chapter 5 reference methods for raw ground turkey and PIF, respectively, were not significantly different (Table 5 and 6).

Discussion
The results of this validation study show that the PhageDx™ *Salmonella* Assay is an effective alternative to the USDA/FSIS MLG 4.10 for the detection of *Salmonella* in 25 g raw ground turkey and FDA/BAM Chapter 5 for the detection of *Salmonella* in 100 g of milk-based powdered infant formula.

In inclusivity and exclusivity testing, the method was shown to be specific for *Salmonella*, correctly identifying 108 *Salmonella* target strains across both species and six *S. enterica* subspecies and 30 non-target strains. The PhageDx™ *Salmonella* Assay was unable to detect two strains within the inclusivity panel, a strain of *Salmonella enterica, subsp. Arizonae* and of *Salmonella enterica, subsp. Houtenae*. It is unclear as to why these strains were missed since the PhageDx™ *Salmonella* assay was able to detect other members of the subspecies. One explanation is that these strains do not have the receptor(s) required for recognition by the phage. With over 2600 serovars in the genus, it is not surprising that there is a range of diversity that is difficult to encompass entirely. Another explanation may be that the strain has a mechanism that prevents the phage from replicating, thus unable to produce the luciferase reporter (11).

The recombinant phage can be produced consistently and is stable for 6 months when stored appropriately. Robustness testing of the PhageDx™ *Salmonella* Assay indicated that the method works well when the assay parameters (enrichment time, recombinant phage concentration and substrate amount) were varied from the stated protocol.

Independent laboratory testing demonstrated that the PhageDx™ *Salmonella* Assay was able to detect *Salmonella* at low levels in 25 g test portions of raw ground turkey and 100 g test portions of milk-based powdered infant formula, which also contained approximately $3.6 \times 10^6$ CFU/g and $1.8 \times 10^3$ CFU/g background flora, respectively. These studies also demonstrated that the performance of the PhageDx™ *Salmonella* Assay was not statistically different from that of USDA/FSIS MLG 4.10 for 25 g test portions of raw ground turkey or FDA/BAM Chapter 5 for 100 g test portions of milk-based powdered infant formula. An alternative confirmation procedure was shown to be identical to the reference method confirmation procedures.

The PhageDx™ *Salmonella* Assay has a number of advantages over the USDA/FSIS MLG 4.10 and FDA/BAM Chapter 5 reference methods. In addition to being a specific assay, the results are easy to interpret as an RLU endpoint is used.
to determine the outcome of the assay. Another advantage is that PhageDx™ provides a presumptive positive result in as little as 9.5h for raw ground turkey or 18.5 h for powdered infant formula compared to >24 h the case of the USDA/FSIS MLG 4.10 and FDA/BAM Chapter 5 reference methods, respectively. PhageDx™ is also a simple test that involves only five basic steps: enrichment, sampling, infection, substrate addition, and signal readout. Finally, PhageDx™ Assay is a rapid method that offers a considerable time savings alternative compared to the USDA/FSIS MLG 4.10 and FDA/BAM Chapter 5 reference methods.

Conclusion

Results of this validation study support the claim that the PhageDx™ Salmonella Assay is a specific, sensitive, fast, and simple method for the detection of Salmonella in raw ground turkey and milk-based powdered infant formula and is statistically comparable to the USDA/FSIS MLG 4.10 and FDA/BAM Chapter 5 methods, respectively. By using a luciferase-expressing recombinant bacteriophage, the assay was able to detect a single, viable bacterium after 7 h enrichment and a 2 h infection for raw ground turkey and 16 h enrichment and 2 h infection for milk-based powdered infant formula. The PhageDx™ Salmonella Assay thus offers shorter time-to-results compared with the other validated Salmonella detection assays.

Acknowledgments

We would like to thank Thai Dong, Henriett Zahn, Dustin Stevens, Wendy Hahn, Brinna Zimmer, John Paulson, and Eric Schuh for their contribution to the development of this assay.

Submitting Company

Laboratory Corporation of America®
531 South Spring Street, Burlington, NC 27215
Independent Lab Studies

Kateland Koch, Benjamin Bastin, M. Joseph Benzinger, Jr. and James Agin

Q Laboratories Inc., Cincinnati, OH, USA 45204

Reviewers

Yi Chen

U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5100 Paint Branch Pkwy, College Park, MD 20740

Maria Cristina Fernandez

Universidad Maimonides, Hidalgo 775 (esq. Felipe Vallese), C1405BCK Buenos Aires, Argentina

Wayne Ziemer

Consultant 1301 Kristen Lane, Loganville, GA 30052

References

(1) American Society for Microbiology: Foodborne Illness Part 3: How Does Salmonella Make Us Sick? (2019)
    https://www.asm.org/Articles/2019/April/Foodborne-Illness-Part-3-How-does-Salmonella-make

(2) U.S. Department of Agriculture Economic Research Service Cost Estimates of Foodborne Illnesses.
    https://www.ers.usda.gov/data-products/cost-estimates-of-foodborne-illnesses.aspx#48498

(3) Centers for Disease Control and Prevention: Salmonella.
    https://www.cdc.gov/salmonella/general/index.html
(4) World Health Organization: Salmonella contamination in infant formula. [http://www.euro.who.int/en/health-topics/emergencies/pages/news/news/2017/12/salmonella-contamination-of-infant-formula](http://www.euro.who.int/en/health-topics/emergencies/pages/news/news/2017/12/salmonella-contamination-of-infant-formula)

(5) U.S. Department of Agriculture Food Safety and Inspection Service Microbiology Laboratory Manual, Isolation and Identification of Salmonella from Meat, Poultry, Pasteurized Egg, and Siluriformes (Fish) Products and Carcass and Environmental Sponges (2019) [https://www.fsis.usda.gov/wps/wcm/connect/700c05fe-06a2-492a-a6e1-3357f7701f52/mlg-4.pdf?MOD=AJPERES](https://www.fsis.usda.gov/wps/wcm/connect/700c05fe-06a2-492a-a6e1-3357f7701f52/mlg-4.pdf?MOD=AJPERES)

(6) US Food and Drug Administration Bacteriological Analytical Manual, Chapter 5 Salmonella (July 2018) [https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam-chapter-5-salmonella](https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam-chapter-5-salmonella)

(7) Official Methods of Analysis (2019), 21st Ed., Appendix J, AOAC INTERNATIONAL, Gaithersburg, MD, [http://www.eoma.aoac.org/app_j](http://www.eoma.aoac.org/app_j)

(8) U. S. Food and Drug Administration Bacteriological Analytical Manual, Chapter 3 Aerobic Plate Count (January 2001) (Accessed August 2019) [https://www.fda.gov/food/laboratory-methods-food/bam-aerobic-plate-count](https://www.fda.gov/food/laboratory-methods-food/bam-aerobic-plate-count)

(9) Least Cost Formulations, Ltd., MPN Calculator Version 1.6 (Accessed August 2019) [www.lcfltd.com/customer/LCFMPNCalculator.exe](http://www.lcfltd.com/customer/LCFMPNCalculator.exe)

(10) Confirmation and Identification of Salmonella spp., Cronobacter spp. and other Gram Negative Organisms by the Bruker MALDI Biotyper Method: Collaborative Study. First Action OMA 2017.09

(11) Labrie, S. J., Samson, J. E., Moineau, S. Bacteriophage resistance mechanisms. Nature Reviews: Microbiology Vol. 8 (2010) 317-327
| No. | Organism                                  | Serovar                          | Source | Strain No. | Origin          | 7 h enrichment | 18 h enrichment |
|-----|-------------------------------------------|----------------------------------|--------|------------|-----------------|----------------|-----------------|
| 1   | Salmonella enterica, subsp. salamae       | 58:i,13,28:1,5                   | ATCC   | 700151     | Human Urine     | Positive        | ND              |
| 2   | Salmonella enterica, subsp. salamae       | 1:9,12:i,l;w,e,n,x               | ATCC   | 43972      | Unknown         | Positive        | ND              |
| 3   | Salmonella enterica, subsp. salamae       | 47:b:1,5                         | ATCC   | 29931      | Unknown         | Negative        | Positive        |
| 4   | Salmonella enterica; subsp. salamae;      | 1:9,12:i,l;w,e,n,x               | ATCC   | 6959       | Urine           | Positive        | ND              |
| 5   | Salmonella enterica, subsp. arizonae      | Not listed                       | ATCC   | BAA-1577   | Unknown         | Positive        | ND              |
| 6   | Salmonella enterica, subsp. arizonae      | 51:i,22:z:z32:-                  | ATCC   | 13314      | Unknown         | Negative        | Positive        |
| 7   | Salmonella enterica, subsp. arizonae      | Not listed                       | ATCC   | 33952      | Unknown         | Positive        | ND              |
| 8   | Salmonella enterica, subsp. arizonae      | Ar.7:1,2,6 18:z4,z23:-          | ATCC   | 12323      | Unknown         | Positive        | ND              |
| 9   | Salmonella enterica, subsp. arizonae      | [8:1,7,8:3] 63:z4,z32:z57        | ATCC   | 700156     | poultry heart   | Negative        | Negative        |
| 10  | Salmonella enterica, subsp. diarizonae    | 35:i,2                           | ATCC   | BAA-216    | Human blood     | Positive        | ND              |
| 11  | Salmonella enterica, subsp. diarizonae    | Not listed                       | ATCC   | 12325      | Unknown         | Positive        | ND              |
| 12  | Salmonella enterica, subsp. diarizonae    | 47:i,23:z23                      | ATCC   | 29934      | Unknown         | Positive        | ND              |
| 13  | Salmonella enterica, subsp. diarizonae    | Not listed                       | ATCC   | 31241      | Clinical isolate| Positive        | ND              |
| 14  | Salmonella enterica, subsp. diarizonae    | Not listed                       | ATCC   | BAA-1579   | Unknown         | Positive        | ND              |
| 15  | Salmonella enterica, subsp. houtenae      | Not listed                       | USDA   | 51158      | Unknown         | Positive        | ND              |
| 16  | Salmonella enterica, subsp. houtenae      | 45:i,451:z                      | ATCC   | 43974      | Unknown         | Negative        | Negative        |
| 17  | Salmonella enterica, subsp. houtenae      | Not listed                       | ATCC   | BAA-1580   | Unknown         | Positive        | ND              |
| 18  | Salmonella enterica, subsp. indica        | 1:6,14,25:a,g,n,x                | ATCC   | 43976      | Unknown         | Positive        | ND              |
| 19  | Salmonella enterica, subsp. indica        | Not listed                       | ATCC   | BAA-1578   | India           | Positive        | ND              |
| 20  | Salmonella enterica, subsp. Indica        | 1:6,14,25:a,e,n,x                | NCTC   | 10458      | Coconut         | Positive        | Positive        |
| 21  | Salmonella enterica, subsp. Indica        | Not listed                       | Q.Labs | QL 024.62  | Unknown         | Positive        | Positive        |
| 22  | Salmonella enterica, subsp. Indica        | Not listed                       | Q.Labs | QL 18022.6 | Unknown         | Positive        | Positive        |
| 23  | Salmonella bongori                        | 66:z41:z                        | ATCC   | 43975      | Unknown         | Positive        | ND              |
| 24  | Salmonella bongori                        | 66:z41:z                        | NCTC   | 12419      | Unknown         | Positive        | Positive        |
| 25  | Salmonella bongori                        | 66:z41:z                        | NCTC   | 10496      | Frog            | Positive        | Positive        |
| 26  | Salmonella bongori                        | O                               | USDA   | SEP293     | Unknown         | Positive        | ND              |
| 27  | Salmonella enterica, subsp. enterica,     | F                               | ATCC   | 35640      | Creek water     | Positive        | ND              |
| 28  | Salmonella enterica, subsp. enterica,     | B                               | ATCC   | BAA-2162   | Unknown         | Positive        | ND              |
| 29  | Salmonella enterica, subsp. enterica,     | B                               | FDA    | SARB 1     | Peru            | Positive        | ND              |
| 30  | Salmonella enterica, subsp. enterica,     | O                               | University of Iowa | DM5012 | Unknown         | Positive        | ND              |
| 31  | Salmonella enterica, subsp. enterica,     | E                               | USDA   | 41084      | Unknown         | Positive        | ND              |
| 32  | Salmonella enterica, subsp. enterica,     | E                               | FDA    | SARB 2     | Human, WA       | Positive        | ND              |
| 33  | Salmonella enterica, subsp. enterica,     | C                               | University of Georgia | 73 | Unknown         | Positive        | ND              |
| 34  | Salmonella enterica, subsp. enterica,     | E                               | USDA   | AUG071     | Unknown         | Positive        | ND              |
| 35  | Salmonella enterica, subsp. enterica,     | E                               | USDA   | 43972      | Unknown         | Positive        | ND              |
| Salmonella enterica, subsp. enterica, serovar Bispebjerg | B | ATCC | 9842 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Brandenburg | B | USDA | AUG053 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Braenderup | C1 | USDA | 52115 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Breedeney | B | USDA | 61003.2 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Breukelan | C2 | ATCC | 15782 | Cucucus | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Cerro | K | USDA | 310111.1 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Champaign | Q | ATCC | 700139 | hen liver | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Chester | B | ATCC | 11997 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Choleraesuis | 6,7:c;1,5 | ATCC | 10708 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Choleraesuis A | 6,7:c;1,5 | ATCC | 7001 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Derby | B | FDA | SARB 11 | Turkey, PA | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Dublin | D1 | FDA | SL477 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Eko | B | USDA | 33006.2 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Enteritidis | D1 | University of Iowa | 4-50-39 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Gallinarum | C2 | University of Georgia | MH44684 | Swine | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Havana | G | University of Georgia | MH84665 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Heidelberg | B | FDA | SL476 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Hvittingfoss | I | USDA | 63008.2 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Illinois | E1 | ATCC | 11646 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Infantis | C1 | University of Georgia | MH95276 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Javiana | D2 | ATCC | 10721 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Kahla | T | ATCC | 17980 | Feces | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Kalamu | B | USDA | 63279.2 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Kentucky | C2 | ATCC | 9263 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Kiambu | B | USDA | 51316 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Lexington | E1 | University of Georgia | 9492-M | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Liverpool | E2 | USDA | AUG365 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar London | E2 | USDA | JUL218 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Mbandaka | C1 | University of Georgia | 74 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Meleagrisidis | E1 | USDA | FEB095 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Menden | C1 | ATCC | 15992 | Feces | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Minnesota | L | USDA | 52329.1 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Michigan | J | University of Georgia | DM5049 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Mississippi | G | University of Iowa | 102 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Monophasic | Not listed | University of Georgia | 53 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Montevideo | C1 | ATCC | 8387 | Unknown | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Muenchen | C2 | FDA | SARB 35 | Human, NC | Positive | ND |
| Salmonella enterica, subsp. enterica, serovar Muenster | E1 | USDA | 31053 | Unknown | Positive | ND |
| No. | Strain | Source   | Isolate No. | Species | Age | Environment | Source ID | Location | Result | Agency | Notes |
|-----|--------|----------|-------------|---------|-----|-------------|-----------|----------|--------|--------|-------|
| 75  | *Salmonella enterica*, subsp. enterica, serovar Newport | C₂ | FDA | SL317 | Unknown | Positive | ND |
| 76  | *Salmonella enterica*, subsp. enterica, serovar Ngili | C₁ | ATCC | 19127 | Feces | Positive | ND |
| 77  | *Salmonella enterica*, subsp. enterica, serovar Ohio | C₁ | USDA | 52307 | Unknown | Positive | ND |
| 78  | *Salmonella enterica*, subsp. enterica, serovar Oranienburg | C₁ | ATCC | 9239 | Unknown | Positive | ND |
| 79  | *Salmonella enterica*, subsp. enterica, serovar Panama | D₁ | FDA | SARB 40 | Human, NC | Positive | ND |
| 80  | *Salmonella enterica*, subsp. enterica, serovar Paratyphi A | A | ATCC | 9150 | Unknown | Positive | ND |
| 81  | *Salmonella enterica*, subsp. enterica, serovar Paratyphi B | B | USDA | SEP358 | Unknown | Positive | ND |
| 82  | *Salmonella enterica*, subsp. enterica, serovar Paratyphi C | C₁ | ATCC | BAA-1714 | Unknown | Positive | ND |
| 83  | *Salmonella enterica*, subsp. enterica, serovar Pomona | M | University of Iowa | DMSO63 | Unknown | Positive | ND |
| 84  | *Salmonella enterica*, subsp. enterica, serovar Potsdam | C₁ | ATCC | 25957 | Child | Positive | ND |
| 85  | *Salmonella enterica*, subsp. enterica, serovar Pullorum | D₁ | ATCC | 13036 | Egg | Positive | ND |
| 86  | *Salmonella enterica*, subsp. enterica, serovar Reading | B | USDA | 43164.2 | Unknown | Positive | ND |
| 87  | *Salmonella enterica*, subsp. enterica, serovar Remo | F | University of Iowa | DMSO67 | Unknown | Positive | ND |
| 88  | *Salmonella enterica*, subsp. enterica, serovar Rubislaw | B | ATCC | 9712 | Cystitis | Positive | ND |
| 90  | *Salmonella enterica*, subsp. enterica, serovar San Diego | B | USDA | APR025 | Unknown | Positive | ND |
| 91  | *Salmonella enterica*, subsp. enterica, serovar Schwarzengrund | B | USDA | 13092.2 | Unknown | Positive | ND |
| 92  | *Salmonella enterica*, subsp. enterica, serovar Senftenburg | E₄ | FDA | SARB 59 | Chicken, MA | Positive | ND |
| 93  | *Salmonella enterica*, subsp. enterica, serovar Simsbury | E₄ | ATCC | 12004 | Unknown | Positive | ND |
| 94  | *Salmonella enterica*, subsp. enterica, serovar Stanley | B | ATCC | 7308 | Unknown | Positive | ND |
| 95  | *Salmonella enterica*, subsp. enterica, serovar Taksony | E₄ | USDA | 32133 | Unknown | Positive | ND |
| 96  | *Salmonella enterica*, subsp. enterica, serovar Tallahassee | C₂ | ATCC | 12002 | Unknown | Positive | ND |
| 97  | *Salmonella enterica*, subsp. enterica, serovar Tennessee | C₁ | FDA | SL487 | Peanut Butter | Positive | ND |
| 98  | *Salmonella enterica*, subsp. enterica, serovar Thompson | C₁ | University of Georgia | 11842M | Horse | Positive | ND |
| 99  | *Salmonella enterica*, subsp. enterica, serovar Typhi C | C₁ | ATCC | BAA-6539 | Unknown | Positive | ND |
| 100 | *Salmonella enterica*, subsp. enterica, serovar Typhimurium | B | FDA | 1226 | Unknown | Positive | ND |
| 101 | *Salmonella enterica*, subsp. enterica, serovar Typhimurium DT104 | B | FDA | 1294 | Outbreak Set | Positive | ND |
| 102 | *Salmonella enterica*, subsp. enterica, serovar Typhimurium /DT104b | B | FDA | 1278 | Outbreak Set | Positive | ND |
| 103 | *Salmonella enterica*, subsp. enterica, serovar Uganda | E₄ | USDA | 51278.2 | Unknown | Positive | ND |
| 104 | *Salmonella enterica*, subsp. enterica, serovar Urbana | N | ATCC | 9261 | Unknown | Positive | ND |
| 105 | *Salmonella enterica*, subsp. enterica, serovar Vellore | B | ATCC | 15611 | Rectal Swab | Positive | ND |
| 106 | *Salmonella enterica*, subsp. enterica, serovar Vircow | C₁ | ATCC | 51955 | Unknown | Positive | ND |
| 107 | *Salmonella enterica*, subsp. enterica, serovar Wagadugu | E₁ | USDA | 53298 | Unknown | Positive | ND |
| 108 | *Salmonella enterica*, subsp. enterica, serovar Weltevreden | E₁ | ATCC | BAA-2568 | Unknown | Positive | ND |
| 109 | *Salmonella enterica*, subsp. enterica, serovar Worthington | G₂ | ATCC | BAA-2085 | Unknown | Positive | ND |
| 110 | *Salmonella Non-typeable* | Not listed | USDA | 63214 | Unknown | Positive | ND |

¹18 h enrichments were not tested if 7 h enrichments were positive based on the assumption that at 18 h there would be a greater number of cells and thus would also result in a positive result.

²American Type Culture Collection, Manassas, VA.
ND = not done.
Unknown: No information is available on the origin of the strain.
Serovar or antigenic formula not listed for this strain by the source.
U.S. Department of Agriculture, Animal Research Center, Clay Center, NE.
Inclusivity assay performed by Q Laboratories.
National Collection of Type Cultures, Porton Down, Salisbury, UK.
Q Laboratories, Cincinnati, OH.
U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, College Park, MD.
University of Iowa, Iowa City, IA.
University of Georgia, Athens, GA.
| No. | Organism                          | Source | Strain ID | Origin        | PhageDx™ Result |
|-----|----------------------------------|--------|-----------|---------------|-----------------|
| 1   | Acinetobacter baumannii          | ATCC   | 19606     | Urine         | Negative        |
| 2   | Bacillus cereus                  | ATCC   | 14579     | Unknown       | Negative        |
| 3   | Bacillus subtilis subsp. subtilis| ATCC   | 6051      | Unknown       | Negative        |
| 4   | Citrobacter freundii             | ATCC   | 8090      | Unknown       | Negative        |
| 5   | Citrobacter werkmanii            | ATCC   | 51114     | Human blood   | Negative        |
| 6   | Citrobacter youngae              | ATCC   | 29935     | Metal scraps  | Negative        |
| 7   | Citrobacter koseri               | ATCC   | 25408     | Throat        | Negative        |
| 8   | Cronobacter sakazakii            | ATCC   | BAA-894   | Human clinical| Negative        |
| 9   | Escherichia coli                 | ATCC   | 25922     | Clinical      | Negative        |
| 10  | Escherichia coli 0157:H7 (stx-)  | ATCC   | 43888     | Human feces   | Negative        |
| 11  | Edwardsiella tarda               | ATCC   | 15947     | Stool         | Negative        |
| 12  | Enterobacter cloacae subsp. cloacae| ATCC  | 13047     | Spinal Fluid  | Negative        |
| 13  | Enterobacter kobei               | ATCC   | BAA-260   | Human blood   | Negative        |
| 14  | Enterococcus faecium             | ATCC   | 19434     | Unknown       | Negative        |
| 15  | Enterococcus faecalis            | ATCC   | 29212     | Urine         | Negative        |
| 16  | Escherichia fergusonii           | ATCC   | 35469     | Human feces   | Negative        |
| 17  | Escherichia hermanni             | ATCC   | 33650     | Clinical, Toe | Negative        |
| 18  | Hafnia alevi                     | ATCC   | 13337     | Unknown       | Negative        |
| 19  | Klebsiella oxytoca               | ATCC   | 43165     | Clinical      | Negative        |
| 20  | Klebsiella pneumoniae            | ATCC   | 4352      | Cow's milk    | Negative        |
| 21  | Listeria grayi                   | ATCC   | 25401     | Decaying plant material | Negative |
| 22  | Listeria welshimer               | ATCC   | 35897     | Decaying plant material | Negative |
| 23  | Morganella morganii : subsp. Maorganii M11| ATCC | 25830 | Clinical | Negative |
| 24  | Pluralibacter gergoviae          | ATCC   | 33028     | Urine         | Negative        |
| 25  | Proteus mirabilis                | ATCC   | 43071     | Clinical, Toe | Negative        |
| 26  | Pseudomonas aeruginosa; Strain Boston 41401 | ATCC | 27853 | Blood Culture | Negative |
| 27  | Shigella sonnei                  | ATCC   | 9290      | Unknown       | Negative        |
| 28  | Staphylococcus aureus            | ATCC   | 29213     | Wound         | Negative        |
| 29  | Staphylococcus epidermidis       | ATCC   | 14990     | Nose          | Negative        |
| 30  | Yersinia enterocolitica          | ATCC   | 23715     | Human blood   | Negative        |

American Type Culture Collection, Manassas, VA.

Unknown: No information is available on the origin of the strain.
Table 3. Stability and Consistency (lot-to-lot) of PhageDx™ Salmonella Recombinant Phage – POD Comparison

| Phage lot No. | Lot age, months | N\(^a\) | x\(^b\) | POD\(^c\) | 95% CI | 95% CI | dPOD\(^d\) | 95% CI |
|---------------|-----------------|--------|--------|-----------|--------|--------|-----------|--------|
| **Salmonella Typhimurium (target)** |                |        |        |           |        |        |           |        |
| B\(^a\)      | 3               | 10     | 6      | 0.6      | 0.31, 0.83 | C\(^i\) | 1      | 10     | 6      | 0.6 | 0.31, 0.83 | 0.00 | -0.37, 0.37 |
| A\(^i\)      | 6               | 10     | 4      | 0.4      | 0.17, 0.69 | C      | 1      | 10     | 6      | 0.6 | 0.31, 0.83 | -0.20 | -0.53, 0.21 |
| A             | 6               | 10     | 4      | 0.4      | 0.17, 0.69 | B      | 3      | 10     | 6      | 0.6 | 0.31, 0.83 | -0.20 | -0.53, 0.21 |
| **Citrobacter freundii (non-target)** |                |        |        |           |        |        |           |        |
| B             | 3               | 10     | 0      | 0.0      | 0.0, 0.28 | C      | 1      | 10     | 0      | 0.0 | 0.0, 0.28 | 0.0  | -0.28, 0.28 |
| A             | 6               | 10     | 0      | 0.0      | 0.0, 0.28 | C      | 1      | 10     | 0      | 0.0 | 0.0, 0.28 | 0.0  | -0.28, 0.28 |
| A             | 6               | 10     | 0      | 0.0      | 0.0, 0.28 | B      | 3      | 10     | 0      | 0.0 | 0.0, 0.28 | 0.0  | -0.28, 0.28 |

\(^a\)N = Number of test portions.
\(^b\)x = Number of positive test portions.
\(^c\)PODA = Positive outcomes divided by the total number of trials first member of pair.
\(^d\)PODB = Positive outcomes divided by the total number of trials second member of pair.
\(^e\)dPOD\(_{AB}\) = Difference in POD between the paired comparison.
\(^f\)95% CI = If the confidence interval of a dPOD does not contain zero, then the difference is statistically significant at the 5% level.

\(^g\)Lot A was produced 12/18.
\(^h\)Lot B was produced 03/19.
\(^i\)Lot C was produced 08/19.
Table 4. Robustness study: Impact of Varying Enrichment time, Phage Concentration, Lysis/Luciferase Master Mix Concentration on PhageDx™
*Salmonella* Assay Results – POD Comparison

| Test Condition¹ | Enrichment time | Volume phage | Volume substrate | Nᵇ | xᶜ | POD₉ᵈ | 95% CI | xᶜ | POD₉ᵈ | 95% CI | dPOD₉¹ᵈ | 95% CI |
|-----------------|-----------------|--------------|------------------|----|----|--------|--------|----|--------|--------|----------|--------|
| Raw ground turkey – spiked with *S*. Heidelberg (target) | | | | | | | | | | | | |
| 1 | 6.5 h | 8 µL | 60 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| 2 | 6.5 h | 8 µL | 70 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| 3 | 6.5 h | 12 µL | 60 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| 4 | 6.5 h | 12 µL | 70 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| 5 | 24 h | 8 µL | 60 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| 6 | 24 h | 8 µL | 70 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| 7 | 24 h | 12 µL | 60 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| 8 | 24 h | 12 µL | 70 | 10 | 7 | 0.7 | 0.40, 0.89 | 7 | 0.7 | 0.40, 0.89 | 0.0 | -0.25-0.25 |
| Raw ground turkey – unspiked (non-target) | | | | | | | | | | | | |
| 1 | 6.5 h | 8 µL | 60 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |
| 2 | 6.5 h | 8 µL | 70 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |
| 3 | 6.5 h | 12 µL | 60 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |
| 4 | 6.5 h | 12 µL | 70 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |
| 5 | 24 h | 8 µL | 60 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |
| 6 | 24 h | 8 µL | 70 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |
| 7 | 24 h | 12 µL | 60 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |
| 8 | 24 h | 12 µL | 70 | 10 | 0 | 0.0 | 0.00, 0.28 | 0 | 0.0 | 0.00, 0.28 | 0.0 | -0.25, 0.25 |

¹Each test condition is being compared to the nominal test condition.
ᵇN = Number of test portions per condition.
ᶜx = Number of positive test portions per condition.
dPOD_T = Positive outcomes divided by the total number of trials per condition.
Nominal condition = 7 h enrichment, 10 µL phage, 65 µL lysis/luciferase master mix substrate.

fPOD_N = Positive outcomes divided by the total number of trials per nominal condition.

gdPOD_TN = Difference in POD between the test condition and nominal condition.
h95% CI = If the confidence interval of a dPOD does not contain zero, then the difference is statistically significant at the 5% level.
Table 5. PhageDx™ *Salmonella* Assay Results vs. Reference Method Comparison Results

| Matrixa | Strain               | Enrichment Time Pointb | MPNc/test portiond | Nxe | PODCSEP | 95% CI     | Reference Method Result | PODCSEP | 95% CI | dPODcSEP | 95% CI |
|---------|----------------------|------------------------|---------------------|-----|---------|-------------|------------------------|---------|--------|----------|--------|
| Raw Ground Turkey (25 g) | *Salmonella* Enteritidis ATCC 13076 | 7 and 18 h           | N/Ai                | 5   | 0       | 0.00, 0.43  | 0                      | 0.00   | 0.00, 0.43 | 0.00     | -0.43, 0.43 |
| Powdered Infant Formula Milk-based (100 g) | *Salmonella* Typhimurium ATCC BAA-215 | 16 and 24 h             | N/Ai                | 5   | 0       | 0.00, 0.43  | 0                      | 0.00   | 0.00, 0.43 | 0.00     | -0.43, 0.43 |

aBoth enrichment time points produced identical results.
bMatrix study was unpaired and analyzed by the unpaired POD statistical analysis.
cMPN = Most Probable Number is based on the POD of reference method test portions using the Least Cost Formulations MPN calculator, with 95% confidence interval.
dN = Number of test portions.
eX = Number of positive test portions.
fPODCSP = Candidate method presumptive positive outcomes confirmed positive.
gPODCCS = Reference method confirmed positive outcomes divided by the total number of trials.
hdPODcSP = Difference between the candidate method and reference method POD values.
i95% CI = If the confidence interval of a dPOD does not contain zero, then the difference is statistically significant at the 5% level.
jMatrix tested by the independent laboratory.
kATCC = American Type Culture Collection, Manassas, VA.
lN/A = Not applicable.
| Matrix                      | Strain          | Enrichment Time Points<sup>a</sup> | MPN<sup>b</sup>/test portion | N<sup>c</sup> | Presumptive | Confirmed | dPOD<sub>CP</sub><sup>f</sup> | 95% CI | 95% CI | dPOD<sub>CP</sub><sup>f</sup> | 95% CI |
|-----------------------------|-----------------|------------------------------------|------------------------------|--------------|-------------|-----------|----------------|-------|-------|----------------|-------|
| Raw Ground Turkey (25 g)<sup>i</sup> | *Salmonella* Enteritidis ATCC 13076 | 7 and 18 h | 0.55 (0.29, 0.93) | 20 | 7 | 0.35 | 0.18, 0.57 | 7 | 0.35 | 0.18, 0.57 | 0.00 | -0.28, 0.28 |
|                            |                 |                                    | 2.76 (1.51, 5.78) | 5 | 5 | 1.00 | 0.57, 1.00 | 5 | 1.00 | 0.57, 1.00 | 0.00 | -0.47, 0.47 |
| Powdered Infant Formula Milk-based (100g)<sup>j</sup> | *Salmonella* Typhimurium ATCC BAA-215 | 16 and 24 h | 0.68 (0.39, 1.12) | 20 | 9 | 0.45 | 0.26, 0.66 | 9 | 0.45 | 0.26, 0.66 | 0.00 | -0.28, 0.28 |
|                            |                 |                                    | 3.70 (1.52, 9.02) | 5 | 5 | 1.00 | 0.57, 1.00 | 5 | 1.00 | 0.57, 1.00 | 0.00 | -0.47, 0.47 |

<sup>a</sup>Both enrichment time points produced identical results.
<sup>b</sup>MPN = Most Probable Number is based on the POD of reference method test portions using the Least Cost Formulations MPN calculator, with 95% confidence interval.
<sup>c</sup>N = Number of test portions.
<sup>d</sup>x = Number of positive test portions.
<sup>e</sup>POD<sub>CP</sub> = Candidate method presumptive positive outcomes divided by the total number of trials.
<sup>f</sup>POD<sub>CC</sub> = Candidate method confirmed positive (per BAM Ch. 5) outcomes divided by the total number of trials.
<sup>g</sup>dPOD<sub>CP</sub> = Difference between the candidate method presumptive result and candidate method confirmed result POD values.
<sup>h</sup>95% CI = If the confidence interval of a dPOD does not contain zero, then the difference is statistically significant at the 5% level.
<sup>i</sup>Matrix tested by the independent laboratory.
<sup>j</sup>ATCC = American Type Culture Collection, Manassas, VA.
<sup>k</sup>N/A = Not applicable.
<sup>l</sup>Results for candidate method presumptive, candidate method confirmed, and reference method were identical.